Mustang Bio, Inc. (MBIO)
Oxford Ledge is still expanding full research coverage of MBIO. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Mustang Bio develops combination cancer therapies licensed from research institutions through clinical trials without yet generating product sales.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-05
- 8-K Delisting / transfer of listing 2026-04-17
- 10-K Annual financial report with audited statements 2026-03-19
- 8-K Shareholder vote results; Other material event; Financial statements and exhibits 2025-12-23
- DEF 14A Proxy statement for shareholder vote 2025-12-03
Source: SEC EDGAR.
Annual results
5 years of annual figures for MBIO, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$1.9M | -$0.39 |
| 2024 | — | -$15.8M | -$38.57 |
| 2023 | — | -$51.6M | -$299.95 |
| 2022 | — | -$77.5M | -$10.09 |
| 2021 | — | -$66.4M | -$0.76 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for MBIO. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open MBIO in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.